NCT05544656View on ClinicalTrials.gov

"The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain BETA"

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
Low Back Pain
Interventions
DRUG

Tolperisone Hydrochloride

Tolperisone Hydrochloride tablets of 150 mg, administered three times a day

DRUG

Placebo

matching placebo administered three times a day

Trial Locations (1)

H-1083

Department of Neurology, Semmelweis University, Budapest

All Listed Sponsors
collaborator

National Research Develpment and Innovation Fund, Hungary

UNKNOWN

collaborator

MEDITOP Pharmaceutical LTD, Hungary

UNKNOWN

lead

Semmelweis University

OTHER

NCT05544656 - "The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain BETA" | Biotech Hunter | Biotech Hunter